Large Study: GLP-1 Drugs Significantly Reduce Risk of New, Worsening Addictions
LLY sits 61% above its 52-week low of $623.78.
Summary
A large study published in The BMJ indicates that GLP-1 drugs, including Eli Lilly's Mounjaro and Trulicity, significantly protect against the development of new substance use disorders and alleviate existing addictions across a broad spectrum of substances like alcohol, opioids, cocaine, nicotine, and cannabis. The study found a 14% lower odds of developing a new substance use disorder and substantial reductions in related emergency department visits (31%), hospital admissions (26%), deaths (50%), and overdoses (39%). This groundbreaking finding suggests a common biological pathway for addiction treatable by GLP-1s, potentially opening a massive new therapeutic market beyond diabetes and obesity. This development could materially expand the long-term revenue potential and investment thesis for companies like Eli Lilly. Investors should monitor upcoming clinical trials, such as the VA's planned study on semaglutide for alcohol use disorder, and potential regulatory pathways for addiction indications.
At the time of this announcement, LLY was trading at $1,002.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $946.7B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.